Adding Pen-Transplant Rituximab To Nonmyeloablative (Nma) Conditioning Before Allogeneic Hematopoietic Cell Transplantation (Allo-Hct) To Improve Disease-Related Outcomes In Patients With Chronic Lymphocytic Leukemia (Cll): Phase Ii Clinical Trial.

JOURNAL OF CLINICAL ONCOLOGY(2016)

引用 0|浏览18
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要